Session Synopsis: Precision Medicine’s value is undeniable. But what about its financial impact? And how should we assess its value beyond the field of oncology? This session will cover the unsustainable economics at play, reimbursement challenges and policies, and cost-based pricing versus value-based pricing, from a patient, pharma, payor, and molecular diagnostics perspective.
Session Chair Profile
Ph.D., Complex Adaptive Systems Initiative Chief Scientist, Regents’ Professor, Del E. Webb Chair in Health Innovation, ASU
Dr. George Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI), Regents’ Professor and Del E. Webb Chair in Health Innovation at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine. He founded the Biodesign Institute at ASU and served as Director for 2003 to 2009. In creating this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $300 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. He serves on the Board of Directors of Monsanto (since 2003), Exelixis (since 2004), Caris Life Sciences (since 2005), and the Scientific Advisory Board of Synthetic Genomics (since 2009). From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as ‘R&D Scientist of the Year’ by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in 2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry.
Dr. Roy Beveridge is Humana’s Senior Vice President and Chief Medical Officer, where he is responsible for developing and implementing the company’s clinical strategy and advancing its integrated care delivery model. He is known for creating collaborative environments among physician communities and providing thought leadership, publishing extensively in the fields of medical oncology, quality design, ethics, and population health. Previously, Dr. Beveridge served as Chief Medical Officer for McKesson Specialty Health and as Executive VP and Chief Medical Officer for US Oncology. He practiced for more than 20 years in medical oncology and stem cell transplant in northern Virginia.
M.D., Deputy Chief Medical Officer for the Centers for Medicare and Medicaid Services
Dr. Shari M. Ling is the Deputy Chief Medical Officer for the Centers for Medicare and Medicaid Services (CMS), and Medical Officer in the Center for Clinical Standards and Quality (CCSQ). She assists the CMS Chief Medical Officer in the Agency’s pursuit of better health care, healthier populations, and smarter spending. Dr. Ling represents CMS on several Health and Human Services (HHS) efforts. She leads the Clinical Services federal workgroup for the National Alzheimer’s Project Plan, and represents CMS on the workgroups to eliminate and prevent Healthcare Associated Infections (HAIs) and the National Strategy to Combat Antimicrobial Resistance. Dr. Ling is a board certified Geriatrician, Rheumatologist and Internist who received her medical training at Georgetown University School of Medicine and received her clinical training in Internal Medicine and Rheumatology at Georgetown University Medical Center, and Geriatric Medicine training at Johns Hopkins University.
Ph.D., MSC, Associate Member/Professor, Fred Hutchinson Cancer Research Center/University of Washington
Dr. Lotte Steuten is an entrepreneurial academic, striving to accelerate patient access to high-value healthcare innovations. She has global expertise in health economics that she applies to identifying, building and articulating the clinical, humanistic and economic value of precision medicine. As an Associate Member at Fred Hutch and Affiliate Associate Professor at UW, Lotte conducts an active research program in comparative effectiveness research and health policy. She is an advisor to various research organizations, policy boards and healthcare industries, and is co-founder and Chief Scientific Officer of Panaxea – a medtech consulting firm. Lotte accrued her global expertise as at leading health economic groups in the US, UK and the Netherlands. She obtained an MSc in Health Sciences and a PhD (cum laude) in Health Economics from Maastricht University, the Netherlands.